Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate

Latifoltojar, Arash; Δικαίος, Νικόλαος; Ridout, Ashley; Moore, Caroline M.; Illing, Rowland; Kirkham, Alex; Taylor, Stuart A.; Halligan, Steve; Atkinson, David; Allen, Clare; Emberton, Mark; Punwani, Shonit

doi:10.1038/pcan.2015.33

Cited by 21 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority (76%) of the MRI scans were done after biopsy, which is known to reduce the accuracy of MRI, resulting in both under‐ and over‐staging. These post‐biopsy effects can persist for some considerable time, often past the 4 week post‐biopsy recovery period used as the minimum in this series, and in many institutions . Differences in prevalence of pathological ECE (17% in this series vs 32.4% in the series reported by Gaunay et al.…”

mentioning

confidence: 66%

A picture is worth a thousand words… but does it add utility to a nomogram to predict extraprostatic extension?

Moore¹

2018

BJU International

View full text Add to dashboard Cite

mentioning

confidence: 66%

A picture is worth a thousand words… but does it add utility to a nomogram to predict extraprostatic extension?

Moore¹

2018

BJU International

View full text Add to dashboard Cite

“…Regarding the order between MRI examination and biopsy, less than half of the cancers were examined by MRI after biopsy. According to Latifoltojar et al, the ADC values of prostate tissue at 1, 2, and 6 months post-biopsy were not significantly different from pre-biopsy values [29]. Furthermore, we avoided placement of ROIs in hemorrhagic areas.…”

Section: Discussionmentioning

confidence: 92%

Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer

et al. 2019

View full text Add to dashboard Cite

Background: We investigated the usefulness of the minimum ADC value of primary breast lesions for predicting axillary lymph node (LN) status in luminal Alike breast cancers with clinically negative nodes in comparison with the mean ADC. Methods: Forty-four luminal Alike breast cancers without axillary LN metastasis at preoperative clinical evaluation, surgically resected with sentinel LN biopsy, were retrospectively studied. Mean and minimum ADC values of each lesion were measured and statistically compared between LN-positive (n = 12) and LN-negative (n = 32) groups. An ROC curve was drawn to determine the best cutoff value to differentiate LN status. Correlations between mean and minimum ADC values and the number of metastatic axillary LNs were investigated. Results: Mean and minimum ADC values of breast lesions with positive LN were significantly lower than those with negative LN (mean: 839.9 ± 110.9 vs. 1022.2 ± 250.0 × 10-6 mm 2 /s, p = 0.027, minimum: 696.7 ± 128.0 vs. 925.0 ± 257.6 × 10-6 mm 2 /s, p = 0.004). The sensitivity and NPV using the best cutoff value from ROC using both mean and minimum ADC were 100%. AUC of the minimum ADC (0.784) was higher than that of the mean ADC (0.719). Statistically significant negative correlations were observed between both mean and minimum ADCs and number of positive LNs, with p. 2 stronger correlation to minimum ADC than mean ADC. Conclusions: The minimum ADC value of primary breast lesions predicts axillary LN metastasis in luminal Alike breast cancer with clinically negative nodes, with high sensitivity and high NPV.

show abstract

“…The biomarker kinetic changes following biopsy are poorly described, however we expect these will be minimally affected by biopsy artefacts with 8 weeks of treatment and healing. Latifoltojar and colleagues examined changes in mpMRI parameters following biopsy and described a return to baseline apparent diffusion coefficient (ADC) parameters 1 month post biopsy [25]. The effects of biopsy on MRS parameters are currently unknown and will be examined in this study.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol

Roberts

Yaxley

Coughlin

et al. 2016

Contemporary Clinical Trials

View full text Add to dashboard Cite

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT BackgroundAtorvastatin and metformin are known energy restricting mimetic agents that act synergistically to produce molecular and metabolic changes in advanced prostate cancer (PCa). This trial seeks to determine whether these drugs favourably alter selected parameters in men with clinicallylocalized, aggressive PCa. Methods/designThis prospective phase II randomized, controlled window trial is recruiting men with clinically significant PCa, confirmed by biopsy following multiparametric MRI and intending to undergo radical prostatectomy. Ethical approval was granted by the Royal Brisbane and Women"s

show abstract

Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate

Cited by 21 publications

References 23 publications

A picture is worth a thousand words… but does it add utility to a nomogram to predict extraprostatic extension?

A picture is worth a thousand words… but does it add utility to a nomogram to predict extraprostatic extension?

Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol

Contact Info

Product

Resources

About